Notice

Technology evaluation results of the injection preparation kit and System
File download : 성균관대 BT 강소기업 상생지원센터_기술가치평가서(메인텍).pdf

Anti-cancer (injection) preparation automation device selected as a BIG3 project by applying for a patent in May 2020 and The injection-integrated cylinder pump technology was awarded the highest value before product sales as a result of the ACPi patent technology evaluation by the Technology Credit Guarantee Fund (Technology New Report) with the project budget (about KRW 20 million) of the BIG3 project support organization. (Please, find the attached file)


With patented technology, the highest evaluation amount in the technology new report before sales does not exceed 500 million won and in general, an evaluation of 300 million won is common.

The result of valuation of 500 million won as a patented technology that has been commercialized and did not generate sales proves that ACPi is the best technology.

With manual ACPi and CAM which the concept design was completed, the production was completed this month with, Yesterday's Korea University and today's National Cancer Center were mostly satisfied with the results of market research with 3D animation videos.


The CAM that the company will develop is when a pharmacist who prepares an anticancer drug puts the anticancer drug bottle on the cup holder and operates the switch and the MCSTD (CSTD developed by the company) is automatically connected to the anticancer drug bottle and converted into an extraction mode. When extracting anticancer drugs with a syringe, it is not easy to extract the entire amount as high as the height of the injection needle, so we will solve the difficulty to extract the entire amount.

CAM is a technology that ACPi V100 extracts the entire amount without leakage because the MCSTD and the anticancer bottle are closely contacted during the preparation process.

It is expected to be well received by pharmaceutical pharmacists, which solves a large part of the ease of preparation and the risk of exposure to cancer drugs. The weight is also less than 5Kg and it is compact, so it seems that CAM alone will have considerable meaning.


As a result of marketization that meets the highest technology value evaluation before product sales, we will do our best to achieve the patented technology value of several trillion won that the company targets.

Thank you for the hard work of Sungkyunkwan University Dr. Kang Soo-Jung and all of the people involved in doing their best for the evaluation.


Thank you.

Next Video clip for patented technology MCST, manual ACPi V100 including CAM
Prev MFDS (KFDA) approval of Anyfusion blood transfusion pump (BTP) and Development of CAM